PriceTargets.com logo

NASDAQ:NBSE - NeuBase Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.33
  • Forecasted Upside: 304.29 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$4.04 As of 10/22/2021 01:00 AM ET
▼ -0.14 (-3.35%)

This chart shows the closing price for NBSE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuBase Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBSE

Analyst Price Target is $16.33
▲ +304.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for NeuBase Therapeutics in the last 3 months. The average price target is $16.33, with a high forecast of $17.00 and a low forecast of $15.00. The average price target represents a 304.29% upside from the last price of $4.04.

This chart shows the closing price for NBSE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in NeuBase Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/13/2021HC WainwrightReiterated RatingBuy$15.00High
6/1/2021HC WainwrightLower Price TargetBuy$18.00 ➝ $15.00Low
3/18/2021OppenheimerReiterated RatingBuy$17.00High
2/12/2021HC WainwrightBoost Price TargetBuy$15.00 ➝ $18.00Low
12/27/2020Royal Bank of CanadaReiterated RatingBuy$17.00N/A
12/17/2020HC WainwrightReiterated RatingBuyMedium
8/16/2020Royal Bank of CanadaReiterated RatingBuy$16.00Medium
8/14/2020Chardan CapitalReiterated RatingBuyHigh
7/16/2020OppenheimerReiterated RatingBuy$17.00Low
6/16/2020Royal Bank of CanadaInitiated CoverageOutperform$16.00High
5/19/2020HC WainwrightReiterated RatingBuy$15.00Low
5/18/2020OppenheimerInitiated CoverageBuy$17.00Low
5/6/2020HC WainwrightReiterated RatingBuy$15.00Low
4/1/2020OppenheimerBoost Price TargetOutperform$14.00 ➝ $17.00High
4/1/2020Chardan CapitalBoost Price TargetBuy$14.00 ➝ $18.00High
3/19/2020Chardan CapitalReiterated RatingBuy$14.00High
3/6/2020Chardan CapitalInitiated CoverageBuy$14.00Medium
2/6/2020GuggenheimInitiated CoverageBuy$13.00High
12/2/2019HC WainwrightReiterated RatingBuy$14.00High
11/20/2019OppenheimerInitiated CoverageOutperform$14.00High
10/29/2019HC WainwrightInitiated CoverageBuy$14.00High
9/24/2019BTIG ResearchInitiated CoverageBuy$15.00High
(Data available from 10/24/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2021

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
NeuBase Therapeutics logo
NeuBase Therapeutics, Inc. is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
Read More

Today's Range

Now: $4.04
Low: $3.98
High: $4.22

50 Day Range

MA: $3.74
Low: $3.27
High: $4.06

52 Week Range

Now: $4.04
Low: $3.26
High: $12.89

Volume

127,362 shs

Average Volume

277,003 shs

Market Capitalization

$132.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuBase Therapeutics?

The following Wall Street analysts have issued stock ratings on NeuBase Therapeutics in the last twelve months: HC Wainwright, Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for NBSE.

What is the current price target for NeuBase Therapeutics?

3 Wall Street analysts have set twelve-month price targets for NeuBase Therapeutics in the last year. Their average twelve-month price target is $16.33, suggesting a possible upside of 304.3%. Oppenheimer Holdings Inc. has the highest price target set, predicting NBSE will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for NeuBase Therapeutics in the next year.
View the latest price targets for NBSE.

What is the current consensus analyst rating for NeuBase Therapeutics?

NeuBase Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NBSE will outperform the market and that investors should add to their positions of NeuBase Therapeutics.
View the latest ratings for NBSE.

What other companies compete with NeuBase Therapeutics?

Other companies that are similar to NeuBase Therapeutics include SIGA Technologies, Rallybio, Adagene, Clovis Oncology, Akebia Therapeutics, Basilea Pharmaceutica, Eliem Therapeutics, Vaccitech, Zomedica, Chinook Therapeutics, BELLUS Health, Pharvaris, Summit Therapeutics, Bolt Biotherapeutics and Avadel Pharmaceuticals.

How do I contact NeuBase Therapeutics' investor relations team?

NeuBase Therapeutics' physical mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company's listed phone number is (164) 645-1790 and its investor relations email address is [email protected] The official website for NeuBase Therapeutics is www.neubasetherapeutics.com.